Complement-based Drug Development Summit 2026

The Complement-based Drug Development Summit is the first industry-dedicated meeting that focuses on the research and development of therapeutics to inhibit the complement pathway, providing safe and effective cures for a range of disease indications. Across 3 content-packed days, the field's thought leaders from Alexion, True North, GSK, Alnylam and many more will be sharing their insight and lessons learned, collectively enabling the community to: - Standardize Efficacy Assessment: Define the next steps toward achieving standardization of robust, functional assays in order to accurately determine treatment efficacy. - Optimize Clinical Trial Design: Analyze methods for improving clinical trial design with case studies in patient recruitment and stratification, targeting, dosing, endpoints and sample handling. - Manage Off-Target Effects: Enhance the management of off-target effects and approaches for minimizing infection risk. - Achieve Regulatory Approval: Learn how best to navigate the regulatory landscape, examining guidelines and expectations to ensure that drugs gain market approval smoothly. - Assess Inhibition Points: Analyze the most effective points of complement inhibition for the treatment of individual diseases and the selection of therapeutic approaches for inhibition.

When is Complement-based Drug Development Summit?

8–10 Dec 2026 — dates announced on the organiser's website.

Where is it held?

The 2017 edition was at Hyatt Regency Boston, Boston, Massachusetts. The organiser hasn't confirmed the venue for this edition yet.

Who organises it?

Hanson Wade.